$AVR

L1 Capital Pty Ltd sold $5.8M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 627,659 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $9.22 ($9.10–$9.30, $5.79M total) across 2 trades over 2026-08-10 to 2026-08-11.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 12, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 10:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A reported open-market sale of about $5.79M worth of shares can influence short-term sentiment and trading flows, but it does not constitute new operational or financial guidance.

02

Market read

Traders may monitor AVR for sentiment effects around insider-related selling, but the filing alone is unlikely to drive a durable repricing without accompanying fundamentals.

03

What to watch

The trades are indirect holdings and the filing does not provide the reason for sale; absence of a stated 10b5-1 plan can be misread without additional context.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-12, covering sales dated 2026-08-10 to 2026-08-11

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp (AVR) by L1 Capital Pty Ltd, identified as a 10% owner with indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 627,659 Anteris Technologies Global Corp shares in open-market trades at about $9.10 to $9.30.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows transaction size and pricing, but it is not a guidance, contract, or regulatory catalyst; also no 10b5-1 plan is indicated, which can increase attention but not guarantee directionality.

Market effects

No direct sector read-through; this is a single-issuer ownership transaction.

None indicated.

None indicated.

Counterpoint

The sale may be liquidity-driven or part of a broader portfolio rebalancing, so it may not signal negative company outlook.

Key entities

  • Anteris Technologies Global Corp

    Subject of the Form 4 disclosure, ticker AVR.

  • L1 Capital Pty Ltd

    Reporter of the indirect open-market sale of AVR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.